Opiant Pharmaceuticals Inc (OPNT) – Strategy, SWOT and Corporate Finance Report
- Pages: 55
- Published: December 2022
- Report Code: MLPH202602FSA
Opiant Pharmaceuticals Inc (OPNT) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company
Key Highlights
Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction, and eating disorders. It focuses on developing treatments to reverse opioid overdoses, alcohol use disorder, acute cannabinoid overdose, and opioid use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by its partner, Adapt Pharma. Opiant is headquartered in Santa Monica, California, the US.
Scope
• Detailed information on Opiant Pharmaceuticals Inc required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Opiant Pharmaceuticals Inc in the form of a SWOT analysis
• An in-depth view of the business model of Opiant Pharmaceuticals Inc including a breakdown and examination of key business segments
• News about Opiant Pharmaceuticals Inc, such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
• Gain understanding of Opiant Pharmaceuticals Inc and the factors that influence its strategies.• Track strategic initiatives of the company and latest corporate news and actions.
• Assess Opiant Pharmaceuticals Inc as a prospective partner, vendor or supplier.
• Support sales activities by understanding your customers' businesses better.
• Stay up to date on Opiant Pharmaceuticals Incs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
Camurus AB
BioDelivery Sciences International Inc
Orexo AB
Avalo Therapeutics Inc
Shire Pharmaceuticals International UC
Alkermes Plc
BioCorRx Inc
H. Lundbeck AS
Indivior Plc
Shire Pharmaceuticals International UC
Orexo AB
Indivior Plc
H. Lundbeck AS
Camurus AB
BioDelivery Sciences International Inc
BioCorRx Inc
Avalo Therapeutics Inc
Alkermes Plc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.